Expertise
We have a wealth of expertise at the global, continental, national, regional, local, and hospital level.
We have an understanding of the patient-centered and market access environments across the globe – our work often covers a global, US or European scope, and in addition, we also have extensive experience in supporting clients with projects in emerging markets throughout the world including Canada, China, India, Japan, Mexico, South Africa, South Korea, and many other countries throughout Africa, Central and South America, Asia and Australasia.
Payer, Pricing & Reimbursement
Garnering the payer perspective is a crucial step to refining and validating the value proposition. There are 3 key elements to a successful payer research project: great links with decision-makers, intimate knowledge of the markets, and understanding the importance of context in terms of payer decision-making processes and analyses. We have a dedicated team of experts who help clients navigate this complex, varied and evolving landscape to optimise market access, value strategy and commercialization across key markets.
To find out our expertise, click on one of the areas below
Pet owners’ preferences for quality-of-life improvements and costs related to innovative therapies in feline pain associated with osteoarthritis
LEARN MORE
Utilising payer research to inform early development of an orphan disease treatment
LEARN MORE
Estimating the direct healthcare costs of treating patients with treatment-resistant depression
LEARN MORE
Eliciting expert consensus to support a new product for a rare disease
LEARN MORE
Established market pricing for a novel renal transplant immunosuppressant
LEARN MORE
Anticipating payer objections and policy barriers to inform market access
LEARN MORE
Securing pricing and reimbursement for a product in 17 EU countries
LEARN MORE
Key publications
Stakeholder insights, WTP, delphi sensus, payer archetype, payer mapping, payer assessments, due diligence, pricing
- Scully M, Dutt T, Lester W, Farrington E, Lockwood S, Perry R, Holmes S. Unmet needs in the management of immune-mediated thrombotic thrombocytopenic purpura and the potential role of caplacizumab in the UK—A modified-Delphi study. eJHaem, 2022, 3;3;619-627
- Rousseau B, Johnson B, Topachevskyi O, Volovyk A. Web-based budget impact and pricing scenarios planning model: Example from the United Kingdom. Value in Health 2016, Volume 19, Issue 3, A79
- Hartz S, Liu-Leage S, Paget M, Pollard C, Cook J, Enstone A. Elicitation of health state utilities associated with varying severities of flare in systemic lupus erythematosus. Health and Quality of Life Outcomes 2015, 13:66
- Hartz S, Liu-Leage S, Paget M, Pollard C, Enstone A. Elicitation of health state utilities associated with varying severities of flare in systemic lupus erythematosus. Value in Health 2014, Volume 17, Issue 7, A331
- Iqbal I, Dasgupta B, Taylor P, Heron L, Pilling C. Elicitation of health state utilities associated with different durations of morning stiffness in rheumatoid arthritis. J Med Econ 2012;15:1192
Conference presentations
- Franceschini M, Heuser M, Cochrane J, O’Donovan P, Perry R. Real-world assessment of orphan drugs via the new Joint Clinical Assessment route in Europe. Poster presented at ISPOR, November 2022
- Borentain S, Nash A, Daly E, Joshi K, O’Hara M, Zhang Q, Mathews M, Haughey S, Richards S, Anjo J, Zante D, Perry R. Clinical consensus regarding the importance of rapid reduction in depressive symptoms in major depressive disorder with acute suicidal ideation or behavior (MDSI). Abstract presented at the European Psychiatric Association, June 2022
- Longstaff L, Bartram D, Gildea E, Wright A, Riley D, Nagda N, DiPietrantonio K, Enstone A, Wyn R. Pet owners’ willingness to pay for therapy outcomes in feline pain associated with osteoarthritis. Abstract presented at BSAVA, May 2021
- Nash A, Borentain S, O’Hara M, Zhang Q, Barbreau S, Haughey S, Bossie C, Daly E, Mathews M, Ming T, Denee T, Nagda N, Riley D, Perry R. Treatment-resistant depression: Expert consensus identified real-world experience and individualized care as key considerations for novel treatments in major depressive disorder. Poster presented at the virtual National Network of Depression Centers conference, September 2021
- Zhang Q, O’Hara M, Zante D, Pone E, Fadeyi I, Hopwood N, Perry R. The use of healthcare resource utilization costs for treatment-resistant depression as evidence for decision-making in the Canadian healthcare system. Poster presented at the virtual 2020 CADTH Symposium
- Oliver L, Karakusevic A, Enstone A, Rousseau B. Understanding the pricing and reimbursement (P&R) landscape of orphan drugs in emerging markets. Poster presented at ISPOR, November 2019
- Wellam H, Pepper K, Silvey M, Middleton C, Rider A, Piercy J. Exploring pre and post Agenzia Italiana Del Farmaco (AIFA) reimbursed access to immunotherapy for the treatment of squamous cell carcinoma of the head and neck (SCCHN). Poster presented at ISPOR, November 2019
- Wellam H, Pepper K, Silvey M, Rider A, Piercy J. Interregional inequality in Italian healthcare delivery affects choice of selective estrogen receptor modulators (SERMS) for the treatment of hormone-receptor-positive breast cancer. Poster presented at ISPOR, November 2019
- Bilder D, Lewis M, Bausell H, Jain M, van Backle J, Jha A, Thomas J. Elicitation of health state utility values in phenylketonuria from a modified Delphi panel. Poster presented at the Society for Inherited Metabolic Disorders (SIMD), April 2019
- Hodgson M, Perry R, Ali A, Price J. Insights into the effect of switching to insulin glargine 300 units/ml on HbA1c and daily basal insulin dosage in type 1 diabetes: A treatment-pattern web-based survey in the United Kingdom. Poster presented at the Diabetes UK Professional Conference, March 2018
- Fadeyi I, McLean T, Tavella F, Heron L. Differences in vaccine pricing between high-income and low-income markets. Podium presentation at ISPOR, November 2017
- Rousseau B, Poinas AC, Oliver L, Collings H. Initiatives that impact pricing and reimbursement of orphan (and ultra orphan) drugs: Review of European trends. Poster presented at ISPOR, November 2017
- Rousseau B, Johnson B, Topachevskyi O, Volovyk A. Web-based budget impact and pricing scenarios planning model: Example from the United Kingdom. Poster presented at ISPOR, May 2016
- Seitz L, Lopes S, Vandebrouck T, Parekh WA, Canty E, Robinson A, Ohlson L. Clinician-reported insights of insulin degludec use in Germany and four supporting European countries. Poster presented at ISPOR, November 2015
- Hartz S, Liu-Leage S, Paget M, Pollard C, Cook J, Enstone A. Elicitation of health state utilities associated with varying severities of flare in systemic lupus erythematosus. Podium presentation at ISPOR, November 2014
- Iqbal I, Dasgupta B, Taylor P, Heron L, Pilling C. Elicitation of health state utilities associated with different durations of morning stiffness in rheumatoid arthritis. Poster presented at the British Society for Rheumatology, May 2012